Theriva Biologics, Inc. TOVX
0.22
(0.01)
(4.35%)
as of 25 Sep
- Market cap
- $10.6M
- P/E
- 0.2×
Follow TOVX
Growth Flags
show if company had growth for consecutive years
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
1.09 | 1.83 | 8.72 | 3.11 | 2.68 | 19.37 | 6.45 | 4.07 | 2.15 | 1.74 |
Net Debt/EBITDA |
0.49 | 0.66 | 1.67 | 0.94 | 0.61 | 4.65 | 1.93 | 1.08 | 0.56 | 0.48 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 2.74% | 2.21% | 1.99% | 0.31% | 0.29% | 0.26% | 4.37% |
Debt/Equity |
0.00 | 0.00 | 0.00 | (0.45) | (0.02) | 0.02 | 0.00 | 0.00 | 0.00 | 0.11 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
1.02 | 0.91 | 0.68 | 0.86 | 0.97 | 0.56 | 0.95 | 1.04 | 0.66 | 0.66 |
Capex/Depreciation |
(3.62) | (0.87) | (0.03) | 0.00 | (0.04) | (0.16) | (1.36) | (1.50) | 0.00 | (0.32) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (315.96%) | 3,813.26% | (1,013.87%) | (1,245.72%) | 158.60% | (83.73%) | (34.16%) | (41.33%) | (91.57%) | (146.58%) | |
| (102.19%) | (107.10%) | (103.27%) | (67.87%) | (97.93%) | (58.87%) | (28.16%) | (28.88%) | (56.65%) | (68.62%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (131.40%) | (96.03%) | (218.10%) | (375.98%) |
Return on Tangible Assets |
(1,002.76%) | (245.36%) | (94.60%) | (139.57%) | (244.20%) | (35.45%) | (51.60%) | (87.02%) | (286.11%) | (328.98%) |
Average Days of Receivables |
0.00 | 0.00 | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 | 0.10 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(2,636.11) | (1,437.75) | (694.22) | (210.84) | (160.22) | (26.47) | (31.31) | (29.80) | (12.56) | (1.38) |
Cash per Share |
1,764.35 | 1,205.35 | 1,161.37 | 228.65 | 81.93 | 138.10 | 68.16 | 35.97 | 8.61 | 1.08 |
Shareholders Equity per Share |
208.24 | (240.14) | 568.63 | (16.06) | (99.21) | 134.17 | 84.54 | 57.37 | 14.14 | 1.27 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
208.24 | (240.14) | 568.63 | (16.06) | (99.21) | 134.17 | 84.54 | 57.37 | 14.14 | 1.27 |
Free Cash Flow |
(28.47) | (20.42) | (17.29) | (13.87) | (12.18) | (12.90) | (19.20) | (19.20) | (16.94) | (16.70) |
Working Capital |
1.81 | 8.15 | 26.13 | 11.15 | 4.97 | 65.30 | 38.46 | 20.67 | 8.70 | 7.45 |
Capital Expenditures |
(0.57) | (0.21) | (0.01) | — | (0.01) | (0.01) | (0.12) | (0.20) | 0.00 | (0.03) |
Net Current Asset Value |
1.32 | (4.30) | 13.53 | (1.87) | (8.02) | 63.90 | 25.49 | 9.15 | 0.00 | (5.39) |
| Other line items | ||||||||||
Quick Ratio |
0.97 | 1.75 | 8.55 | 2.85 | 2.26 | 18.94 | 5.95 | 3.71 | 1.96 | 1.64 |
Depreciation/Fixed assets |
0.17 | 0.28 | 0.45 | 0.65 | 1.16 | 0.86 | 0.25 | 0.32 | 21.23 | 0.49 |
Cash ROIC |
(135.21%) | (153.77%) | (41.52%) | (98.47%) | 1,095.12% | (9.68%) | (20.70%) | (32.20%) | (55.92%) | (56.10%) |
Accounts Receivable Turnover |
0.00 | 0.00 | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(2,583.43) | (1,422.82) | (693.94) | (210.84) | (160.11) | (26.44) | (31.12) | (29.48) | (12.56) | (1.37) |
Capex per Share |
(52.69) | (14.93) | (0.28) | 0.00 | (0.12) | (0.03) | (0.19) | (0.31) | 0.00 | 0.00 |
Average Receivables |
0.30 | 0.12 | — | 0.02 | 0.24 | — | 0.35 | 1.02 | 2.52 | 3.29 |
Average Payables |
3.20 | 2.01 | 1.53 | 1.67 | 1.60 | 0.71 | 0.72 | 0.84 | 0.81 | 0.94 |
Average Assets |
26.67 | 20.67 | 24.49 | 23.69 | 12.82 | 39.39 | 71.11 | 63.54 | 45.29 | 36.80 |
Average Common Equity |
8.63 | (0.58) | 2.49 | 1.29 | (7.92) | 27.70 | 58.62 | 44.40 | 28.02 | 17.23 |
Capex to Sales |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates